Ken Griffin Century Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.44 - $3.29 $2,448 - $5,593	1,700 Added 24.29%	8,700 $14,000
Q2 2024 Aug 14, 2024	SELL	$2.46 - $4.05 $8,856 - $14,580	-3,600 Reduced 33.96%	7,000 $17,000
Q1 2024 May 15, 2024	BUY	$3.19 - $5.32 $23,287 - $38,836	7,300 Added 221.21%	10,600 $44,000
Q4 2023 Feb 14, 2024	BUY	$1.28 - $3.32 $1,536 - $3,984	1,200 Added 57.14%	3,300 $10,000
Q3 2023 Nov 14, 2023	BUY	$2.0 - $3.23 $1,400 - $2,261	700 Added 50.0%	2,100 $4,000
Q2 2023 Aug 14, 2023	SELL	$2.91 - $3.53 $13,386 - $16,238	-4,600 Reduced 76.67%	1,400 $4,000
Q1 2023 May 15, 2023	SELL	$3.4 - $5.11 $183,260 - $275,429	-53,900 Reduced 89.98%	6,000 $20,000
Q4 2022 Feb 14, 2023	SELL	$4.84 - $11.58 $6,292 - $15,054	-1,300 Reduced 2.12%	59,900 $307,000
Q3 2022 Nov 14, 2022	BUY	$8.57 - $13.1 $524,484 - $801,720	61,200 New	61,200 $605,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $71.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.